EPM2AIP1

EPM2AIP1 is a glycogen synthase-associated protein that links the laforin-dependent regulation of glycogen metabolism to whole-body energy homeostasis (PMID:12782127, PMID:24142699). It was first identified as a direct binding partner of laforin (the EPM2A gene product) and colocalizes with laforin in cells and on polyglucosan masses (Lafora bodies) in vivo (PMID:12782127, PMID:15102711). Functionally, EPM2AIP1 modulates the allosteric activation of glycogen synthase by glucose 6-phosphate; in its absence, hepatic glycogen synthesis is reduced, liver fat increases, and animals develop hepatic insulin resistance while being protected from age-related obesity (PMID:24142699). Independently of its metabolic role, EPM2AIP1 is transcribed from a bidirectional promoter shared with MLH1, such that a -93G>A promoter polymorphism reciprocally apportions transcriptional activity between the two genes by altering nuclear-factor binding (PMID:21206982), and methylation of this shared promoter coordinately silences both MLH1 and EPM2AIP1 protein expression in endometrial carcinoma (PMID:34772843, PMID:40468018).

1. 2003 Medium

   Established the first molecular partner of EPM2AIP1, placing it within the laforin signaling/glycogen-disease axis rather than as an orphan protein.

   Evidence Yeast two-hybrid screen of human brain cDNA, coimmunoprecipitation of transfected proteins, and EPM2A deletion-construct mapping with subcellular colocalization

   PMID:12782127

   Open questions at the time

   • Interaction shown for transfected/overexpressed proteins, not at endogenous levels
   • Functional consequence of the laforin-EPM2AIP1 interaction not defined
   • Binding interface on EPM2AIP1 not mapped
2. 2004 Medium

   Demonstrated where EPM2AIP1 acts in disease tissue by localizing it directly on polyglucosan inclusions, connecting it physically to the pathological substrate of Lafora disease.

   Evidence Immunogold electron microscopy and colocalization in a laforin-trap transgenic mouse model

   PMID:15102711

   Open questions at the time

   • Does not establish whether EPM2AIP1 contributes to Lafora body formation or is recruited passively
   • Single localization method in a transgenic trap model
   • No human tissue confirmation in this finding
3. 2013 High

   Resolved the biochemical function of EPM2AIP1 by showing it tunes allosteric activation of glycogen synthase, defining a concrete role in hepatic glycogen synthesis and insulin sensitivity.

   Evidence Epm2aip1 knockout mouse with glycogen synthase activity assays, hepatic glycogen measurement, and metabolic phenotyping

   PMID:24142699

   Open questions at the time

   • Whether EPM2AIP1 binds glycogen synthase directly or acts through laforin is unresolved
   • Structural basis for modulating glucose 6-phosphate allostery unknown
   • Tissue specificity beyond liver not fully characterized
4. 2010 Medium

   Showed that EPM2AIP1 expression is genetically coupled to MLH1 via a shared bidirectional promoter, explaining co-regulation of two functionally unrelated genes.

   Evidence Bidirectional luciferase reporter assays of the MLH1/EPM2AIP1 promoter and EMSA across cell lines

   PMID:21206982

   Open questions at the time

   • Identity of the polymorphism-sensitive nuclear factors not determined
   • In vivo relevance of allele-specific apportioning not established
   • No link between this regulation and EPM2AIP1's metabolic function
5. 2022 Medium

   Demonstrated that promoter methylation coordinately silences EPM2AIP1 with MLH1, making EPM2AIP1 protein loss a correlate of MLH1 epigenetic inactivation in tumors.

   Evidence Immunohistochemistry for EPM2AIP1 correlated with MLH1 promoter methylation by qPCR across 119 endometrial carcinomas, replicated in a second series

   PMID:34772843 PMID:40468018

   Open questions at the time

   • Correlative IHC/methylation data without in vitro mechanistic dissection
   • Functional consequence of EPM2AIP1 loss in tumor cells not tested
   • Whether EPM2AIP1 silencing contributes to tumorigenesis or is a bystander is unknown

• How EPM2AIP1's two distinct contexts — glycogen synthase regulation/laforin binding versus MLH1-coupled transcriptional regulation — relate mechanistically, and whether EPM2AIP1 has an independent function in either, remains open.
• No structure or domain-level mechanism for any EPM2AIP1 activity
• No demonstration of direct glycogen synthase binding
• No causal role established for EPM2AIP1 loss in cancer phenotypes